Compare ARQQ & OCGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARQQ | OCGN |
|---|---|---|
| Founded | 2017 | 2013 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 402.3M | 474.8M |
| IPO Year | 2021 | 2014 |
| Metric | ARQQ | OCGN |
|---|---|---|
| Price | $14.79 | $0.83 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $12.17 |
| AVG Volume (30 Days) | 256.9K | ★ 6.4M |
| Earning Date | 12-08-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $368.30 | $35.04 |
| Revenue Next Year | $214.22 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.52 | $0.69 |
| 52 Week High | $31.75 | $2.73 |
| Indicator | ARQQ | OCGN |
|---|---|---|
| Relative Strength Index (RSI) | 43.37 | 45.98 |
| Support Level | $12.18 | $0.69 |
| Resistance Level | $18.02 | $1.12 |
| Average True Range (ATR) | 1.64 | 0.09 |
| MACD | 0.14 | 0.02 |
| Stochastic Oscillator | 43.80 | 37.96 |
Arqit Quantum Inc is a cybersecurity company that has pioneered a symmetric key agreement technology that makes the communications links of any networked device or data at rest secure against current and future forms of cyber attack - even an attack from a quantum computer. The company delivers its symmetric key agreement technology via its product SKA-Platform. The firm operates in one segment, that is, the provision of cybersecurity services. The company operates and generates its revenue from UK.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").